By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today said that it has been informed by RedPath Integrated Pathology that Medicare may discontinue coverage for RedPath's molecular diagnostic test for pancreatic cancer.

On Wednesday, ExonHit was told by RedPath that CMS contractor Highmark Medicare Services announced its intention to drop coverage of PathFinderTG-Pancreatic cancer, depending on an assessment of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.